Tag Archive for: ARANOTE
FDA Accepts Darolutamide Plus ADT sNDA for mHSPC Treatment
/0 Comments/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxDarolutamide Plus ADT: A Great Treatment Option for Metastatic Hormone-Sensitive Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide ARANOTE artificial intelligence ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment cancer vaccine castration-resistant prostate cancer clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics